Immunome Inc Sustainability Reports
Immunome Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class targeted therapies for oncology. The company leverages its proprietary platform engines to design antibody-drug conjugates, radioligand therapies, and small molecule candidates to improve cancer patient outcomes.
Sector: Manufacturing
Country: United States
Exchange: Nasdaq
FIGI: BBG00BR94298
5 reports from 2020 to 2024
Company Profile
Immunome Inc. is a clinical-stage biopharmaceutical company focused on developing first-in-class and best-in-class targeted therapies for oncology. The company leverages its proprietary platform engines to design antibody-drug conjugates, radioligand therapies, and small molecule candidates to improve cancer patient outcomes.
Reports
5 total
Limited sustainability disclosure available
This company only publishes Annual Reports without dedicated sustainability sections.
